One step prodrug trigger for targeted release of drugs


A tetrazine small-molecule trigger for activating prodrugs has been developed. Active molecules, such as a therapeutic drug or imaging fluorophore, can be caged within a polymer nanoparticle for controlled release at a targeted site.

Cancer cell

APPLICATION

Delivery of therapeutic agents as prodrugs (e.g. Doxorubicin)

Medical imaging

DEVELOPMENT STATUS

Comprehensive in vitro analysis.

IP STATUS

A Patent Cooperation Treaty application has been file.

COMMERCIAL OFFERING

Licensing and/or collaborative research.

OPPORTUNITY


Many drugs cannot be taken directly as they are unstable under physiological conditions and/or toxic. Using a ‘prodrug’ is the common solution, where the drug is masked, and activated by de-masking at the target site. There is a general need for controlled-release drugs that offer a more effective dose and minimise side effects, particularly for cancer treatment. A promising recent approach has sought to exploit a bio-orthogonal reaction using tetrazine as the trigger to unmask the prodrug.

TECHNOLOGY


The vinyl group is small and chemically stable; active molecules with a vinyl ether mask are easier to prepare and less disruptive than current masking groups used with a tetrazine trigger. Custom designed tetrazines are stable under physiological conditions, and allow a controlled rate of reaction. Unmasking by tetrazine is also a one-step reaction, with no catalyst or biological species required, and the by-products are safe. Furthermore, masked molecules can be conjugated within a polymer nanoparticle with linkers that self-immolate upon reaction with tetrazine. This allows targeted and effective release of the active cargo at a specific site, such as a tumour.

Extensive in vitro data; for example, tetrazine-controlled release of Doxorubicin from a Polyethylene Glycol (PEG) nanoparticle to trigger cell death in an environment of prostate cancer cells.

BENEFITS


  • Controlled reactivity, and stable under physiological conditions
  • Exploits a simple bio-orthogonal release reaction with tetrazine
  • Selective release for controlled dose and enhanced cellular uptake
  • Medication is more effective and side-effects are reduced

PUBLICATION


Neumann et al.: Chem. Commun. 2016, 52, 11223 ChemBioChem 2017, 18, 91

Please note, the featured image is purely illustrative.

Enquiry for: One step prodrug trigger for targeted release of drugs

13 + 1 =

CONTACT US

1-7 Roxburgh Street

Edinburgh EH8 9TA

0131 650 9090

SITEMAP

Home                           About Us    

For Business               News and Events  

For Staff       

For Students

 

 

SIGN UP TO OUR NEWSLETTER

Join our conversation and stay up-to-date with the latest innovations, news and upcoming events

News

5 + 12 =

 
Contact Us | Freedom of Information | Cookie Policy | Privacy Statement | Terms and Conditions | Modern Slavery Act